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Introduction
Neutrophil gelatinase-associated lipocalin (NGAL), 
also known as lipocalin-2, LCN2, siderocalin, 24p3, 
is a 25 kDa molecular weight protein. It belongs to 
the lipocalin superfamily, which consists of pro-
teins that transport small hydrophobic molecules 
such as lipids, steroid hormones and retinoids (1). 
This biochemical marker appears to be significant 
in early detection of acute kidney injury, but cur-
rently it has not been sufficiently examined in the 
paediatric population, particularly in newborns 
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population. Although NGAL can be secreted by 
different types of cells, some research data indi-
cate its high diagnostic sensitivity and specificity 
in acute kidney injury. Numerous studies empha-
sise its predictive, diagnostic and prognostic ben-
efits in acute kidney injury (2-8). To date, research 
on urine NGAL in newborn population has includ-
ed certain conditions and illnesses such as asphyx-
ia and sepsis, which might cause acute kidney in-
jury. In most research, reference groups consisted 
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of a small number of healthy newborns (9-12). 
There is not enough data about NGAL concentra-
tion in healthy infants, including both serum and 
urine NGAL, which challenges the probability of 
correct interpretation in different pathological 
conditions. Thus, the aim of the study was to de-
termine the concentration of urine NGAL (uNGAL) 
in healthy term newborns, as well as to determine 
if there was a difference between urine NGAL con-
centration in relation to gender, postnatal age and 
birth weight. The hypothesis was that uNGAL con-
centration does not depend on gender, postnatal 
age and birth weight.
Materials and methods
Subjects 
The present study was prospective and included 
81 healthy newborn (newborns girls, N = 31 and 
newborn boys, N = 50) born at University Hospital 
Mostar, Bosnia and Herzegovina, from April to Oc-
tober 2019. The study was approved by the Ethics 
Committee of the University Clinical Hospital Mo-
star (Ethical approving number 2272/12 at UCHM) 
in adherence to the Declaration of Helsinki. Writ-
ten informed consent was obtained from all par-
ents after explaining the purpose of the study. The 
newborns included in the study were delivered 
from full-term pregnancies and inclusion criteria 
after clinical examination were as follows: gesta-
tional age at birth ≥ 37 weeks, Apgar score ≥ 8 in 
the first minute after birth, C-reactive protein (CRP) 
< 5 mg/L, normal physical and ultrasound exami-
nation (12-14). If routine clinical examination after 
birth showed the presence of infection, cardiac 
disease, congenital anomalies and chromosomal 
disorder, the newborns were excluded from the 
study. 
Methods
The present study used the leftover serum sam-
ples that had previously been analysed in routine 
laboratory tests (mainly bilirubin) required by a ne-
onatologist after the post-delivery examination. 
The leftover serum was used to determine CRP 
concentration, which was the including criteria for 
the study. Venous blood samples were collected in 
Micro sample tubes with gel (Sarstedt, Nümbre-
cht, Germany; volume 1.1 mL) with Micro needles 
23 G (Sarstedt, Nümbrecht, Germany). CRP con-
centration was determined using a CRP Latex rea-
gent kit (Beckman Coulter, Co. Clare, Ireland) on 
Beckman Coulter Chemistry Analyser AU680 
(Beckman Coulter, Brea, USA), controlled two times 
a day (ITA Control Serum Level 1, REF. ODC0014; 
ITA Control Serum Level 2, REF.ODC0015; ITA Con-
trol Serum Level 3, REF.ODC0016). Urine samples (3 
– 5 mL) were obtained within 72 hours after birth 
in paediatric urine sterile collector for newborns 
with a birth weight over 2000 g (B. Braun Medical, 
Saint-Cloud, France) and centrifuged at 400 RCF 
over five minutes and stored at - 80 °C until analy-
sis. Urine NGAL concentration was quantitatively 
determined using original manufacturer Architect 
Urine NGAL reagent kit (REF.1P37, LOT.89159UI00, 
Abbott, Sligo, Ireland) on Architect plus ci8200 an-
alyser (Abbott, Chicago, USA). The Architect Urine 
NGAL assay is a two-step immunoassay for the 
quantitative detection of NGAL in human urine us-
ing chemiluminescent microparticle immunoassay 
(CMIA) technology. The Architect urine NGAL as-
say utilizes a non-competitive, sandwich format 
with chemiluminescent signal detection. The as-
say includes a microparticle reagent prepared by 
covalently attaching an anti-NGAL antibody to 
paramagnetic particles and a conjugate reagent 
prepared by labelling a second anti-NGAL anti-
body with acridinium. Following the immuno-
chemistry steps, the solid phase is washed again 
and the acridinium label is triggered with peroxide 
and base to generate the signal (15). The assay was 
calibrated according to the manufacturer’s instruc-
tions (Architect Urine NGAL Calibrators, Abbott, 
Ireland REF.1P37-01, LOT.86303UI00, 0.0 ng/mL, 
10.0 ng/mL, 100.0 ng/mL, 500.0 ng/mL, 1000.0 ng/
mL, 1500.0 ng/mL) and checked by using commer-
cial controls (Architect Urine NGAL Controls, Ab-
bott, Ireland, REF.1P37-10, LOT.90414UI00, Low 
Control 20.0 ng/mL, Medium Control 200.0 ng/mL, 
High Control 1200.0 ng/mL). According to Archi-
tect Urine NGAL manufacturer’s study, which was 
based on Laboratory Standards Institute (CLSI) 
EP15-A2 guidance, CV was ≤ 6.7%.
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Statistical analysis
Data analysis was performed using Statistica 12.0. 
software (StatSoft, Tulsa, OK, USA). Non-paramet-
ric tests were used because the obtained data 
were not normally distributed (Shapiro Wilk test). 
Measurement data were indicated as median and 
interquartile range (from first (Q1) to the third 
quartile (Q3)), except for gestation age that is pre-
sented as median and minimum – maximum. To 
compare two groups, Mann-Whitney U-test was 
used. Kruskal-Wallis test was used to compare 
more groups. P values < 0.05 were considered sta-
tistically significant.
Results
The study comprised 81 healthy term neonates, 
newborn girls (subgroup F) and newborn boys 
(subgroup M). The respective median gestational 
ages were 39 (37-41) weeks in females, and 40 (37-
41) weeks in males. Median values with an inter-
quartile range along with general characteristics 
of healthy newborns (birth weight, birth length 
and Apgar score) differentiated by gender are 
shown in Table 1. No parameter was shown to be 
statistically significantly different between gen-
ders, although we observed an almost significant 
difference regarding birth weight (P = 0.056). Me-
dian uNGAL concentration in the whole study 
group was 27.1 ng/mL (16.5-56.0 ng/mL). The val-
ues did not differ between genders (P = 0.941), in 
relation to postnatal age (P = 0.863) nor in relation 
to birth weight (P = 0.455) (Table 2). 
Discussion
The study demonstrated that there was no signifi-
cant difference in uNGAL concentration in relation 
to gender, postnatal age and birth weight, which 
supports the hypothesis mentioned beforehand. 
There have been several studies that included uN-
GAL concentration measurement in a healthy 
newborn population. One of these studies, done 
by Chen et al., included measurement of uNGAL in 
38 term newborns when they were three days old. 
The median concentration of uNGAL was 88.1 ng/
Characteristic F (N = 31) M (N = 50) P value*
Gestation age
(weeks) 39.4 (37.0-41.1) 39.6 (37.0-41.4) 0.872
Birth weight (g) 3350 (2950-3600) 3525 (3250-3800) 0.056
Birth length (cm) 54 (53-56) 55 (53-56) 0.134
Apgar score (1 min) 10 (10-10) 10 (10-10) 0.741
Data are presented as the median and interquartile range, except for gestation age that is presented as median and minimum – 
maximum. *Mann-Whitney U-test. F – newborn girls. M – newborn boys. P < 0.05 was considered statistically significant.
Parameter uNGAL (ng/mL) P
Total group (N = 81) 27.1 (16.5-56.0) /
Gender
F (N = 31) 27.1 (15.8-47.9)
0.941*
M (N = 50) 27.9 (16.5-61.0)
Postnatal age
1st day (N = 20) 28.2 (11.7-57.2)
0.863†2nd day (N = 51) 28.9 (16.5-64.2)
3rd day (N = 10) 23.9 (20.2-46.6)
Birth weight
< 3500 g (N = 41) 25.0 (16.5-45.4)
0.455*
≥ 3500 g (N = 40) 30.6 (16.5-64.2)
Data are presented as the median and interquartile range. 
*Mann-Whitney U-test. †Kruskal-Wallis test. P<0.05 was 
considered statistically significant.
Table 1. General characteristics of healthy newborns
Table 2. Urine neutrophil gelatinase-associated lipocalin (uN-
GAL) concentration of healthy newborns 
Biochem Med (Zagreb) 2020;30(3):030706  https://doi.org/10.11613/BM.2020.030706 
4
Mikulić V. et al. uNGAL in healthy newborns in first three days
mL (16). The uNGAL values were higher than in our 
study. Another study by Sarafidis et al. was carried 
out on 22 term infants on their first and third day 
of life. Median urine NGAL concentration on the 
first day of a newborns life was 6.8 ng/mL, while 
this concentration was 7.1 ng/mL on the third day 
(17). Abdelhady et al. carried out a research on a 
control group of 20 newborns and results showed 
the median uNGAL concentration of 9 ng/mL (18). 
The only research carried out on a higher number 
of subjects was conducted by Kamianowska et al. 
(19). This research included 88 term neonates with 
median uNGAL concentration of 16.74 ng/mL. In 
contrast to our study, their study proved that uN-
GAL concentration is significantly higher in female 
newborns. The median concentration of uNGAL 
was 24.16 ng/mL for female neonates and 13.30 
ng/mL for male neonates, P < 0.01. The uNGAL val-
ues in these studies were lower than those ob-
tained by us (17-19). The reasons for the reported 
differences may result from different measure-
ment methods, different manufacture reagents 
and antibodies. Study by Krzeminska et al. on 30 
healthy adults demonstrated that uNGAL concen-
tration obtained by CMIA (Abbott) method was 
significantly higher than ELISA (R&D Systems) (20). 
It is highly important to note that the concentra-
tions in the present study were measured using a 
fully standardized and automated CMIA method, 
as opposed to most above-mentioned studies us-
ing ELISA method from different manufacturers 
(16-19). Similar results to the present study were 
published by Cangemi et al. on 25 newborns and 
the median concentration of uNGAL was 30.3 ng/
mL (CMIA method, Abbott). Also in their study, 
there wasn´t a significant difference regarding uN-
GAL value associated with gender (21). Early re-
search, which examined a possible correlation be-
tween uNGAL, birth weight and postnatal age had 
obtained conflicting results. Two separate studies, 
done by Suchojad et al. and Lavery et al., showed a 
negative correlation between uNGAL and birth 
weight (22,23). On the contrary, our results are in 
concordance with Elmas et al. that showed no dif-
ferences in uNGAL concentrations in regard to 
birth weight (24). The study Seaidi et al. showed 
that postnatal age is associated with uNGAL con-
centration (25). On the other hand, our results 
agree with Lavery et al. study that showed no dif-
ferences in uNGAL concentration regarding post-
natal age  (23). There is a relatively small number of 
studies that deal with uNGAL concentration meas-
urement in healthy children, especially in new-
borns within the first days of life. Moreover, other 
published papers addressing uNGAL concentra-
tion measurement include small groups of sub-
jects or children of different ages. Based on the lit-
erature review, the present study is the first one 
that used automated CMIA method for measure-
ment of urine NGAL concentration over 80 healthy 
term neonates. The big advantage of CMIA meth-
od is the shorter time of measurement of uNGAL 
(in our case about 35 minutes) which is highly im-
portant for routine clinical use, and is less demand-
ing in technical manner. Our findings pointed to-
wards a usable reference range limits for uNGAL 
among the newborn population. However, similar 
to all previous studies, our study had the same po-
tential limitation - we did not use uNGAL/creati-
nine ratio. Our rationale was that at this early stage 
of life creatinine excretion is not constant and 
therefore cannot be used to improve the variabili-
ty of the results due to urine concentration. In con-
clusion, since it was carried out in healthy new-
borns, as expected, the present study showed no 
significant difference in concentration of uNGAL in 
relation to gender, postnatal age and birth weight 
of new-borns. Future studies should include a 
higher number of neonates utilizing the same 
standardized method in order to precisely deter-
mine NGAL reference interval for neonate popula-
tion and thus contribute to the possibility of early 
acute kidney injury recognition in the first days of 
life. 
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